The T-cell Lymphoma Master Repository (TCLMR): A Prospective Databank of Patients With T-cell Lymphoma With Clinical Annotation and Matched Tumor Specimens

Memorial Sloan Kettering Cancer Center26 sites in 1 country1,000 target enrollmentJuly 27, 2023

ConditionsT-cell Lymphoma NK-Cell Lymphoma T-cell Prolymphocytic Leukemia T-cell Large Granular Lymphocytic Leukemia Chronic Lymphoproliferative Disorder of NK Cells Aggressive NK-cell Leukemia Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder)Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form Hydroa Vacciniforme-Like Lymphoproliferative Disorder Adult T-cell Leukemia/Lymphoma Extranodal NK/T-cell Lymphoma, Nasal Type Enteropathy-associated T-cell Lymphoma Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma Intestinal T-Cell Lymphoma, Not Otherwise Specified Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract Hepatosplenic T-cell Lymphoma Subcutaneous Panniculitis-Like T-Cell Lymphoma Mycosis Fungoides Sezary Syndrome Primary Cutaneous Anaplastic Large Cell Lymphoma Primary Cutaneous T-cell Lymphoma Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma Peripheral T-Cell Lymphoma, Not Otherwise Specified Angioimmunoblastic T-cell Lymphoma Follicular T-Cell Lymphoma Nodal Peripheral T-Cell Lymphoma With TFH Phenotype Anaplastic Large Cell Lymphoma, ALK-Positive Anaplastic Large Cell Lymphoma, ALK-negative Breast Implant-Associated Anaplastic Large Cell Lymphoma

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: T-cell Lymphoma
Sponsor: Memorial Sloan Kettering Cancer Center
Enrollment: 1000
Locations: 26
Primary Endpoint: Number of participants populating the T-cell Lymphoma Master Repository/TCLMR
Status: Recruiting
Last Updated: 11 months ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.

Registry

clinicaltrials.gov

Start Date

July 27, 2023

End Date

July 27, 2030

Last Updated

11 months ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Memorial Sloan Kettering Cancer Center

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Written informed consent
•Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy.
•Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines):
•T-cell prolymphocytic leukemia
•T-cell large granular lymphocytic leukemia
•Chronic lymphoproliferative disorder of NK cells
•Aggressive NK-cell leukemia
•Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood
•Chronic active EBV infection of T- and NK-cell type, systemic form
•Hydroa vacciniforme-like lymphoproliferative disorder

Exclusion Criteria

•Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy.
•Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.

Outcomes

Primary Outcomes

Number of participants populating the T-cell Lymphoma Master Repository/TCLMR

Time Frame: 10 years

To develop and populate a secure database comprised of patients with T-cell lymphomas with curated clinical characteristics and treatment outcomes matched to pathological biospecimens.